22 June 2023
BerGenBio ASA – Correction, new share capital and warrants registered
Bergen 22 June 2023: Reference is made to the stock exchange announcement by BerGenBio ASA (the “Company”) on 14 June 2023 regarding the final results of the partially underwritten rights issue of 2,500,000,000 new shares in the Company (the “Offer Shares”) at a subscription price of NOK 0.10 per new share, raising gross proceeds of NOK 250 million (the “Rights Issue”). In addition, the subscribers in the Rights Issue were allocated one warrant for every two Offer Shares allocated to them and paid by them in the Rights Issue (the “Warrants”). The Rights Issue resulted in the issuance of 1,249,999,617 Warrants.
The Warrants and the share capital increase relating to the Rights Issue is now registered with the Norwegian Register of Business Enterprises. After this, the Company’s new registered share capital is NOK 258,866,053.20 divided into 2,588,660,532 shares, each with a nominal value of NOK 0.10.
The Offer Shares and the Warrants are expected to be delivered to investors on 23 June 2023, however trading in the Offer Shares on Oslo Børs with ordinary T+2 settlement may accordingly commence now.
For further information, please contact:
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
This information is published in accordance with the requirements of the Oslo Rule Book II and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
